Lung Cancer, Biomarkers, Fatty Acids
Conditions
Brief summary
This study aims to evaluate the performance of serum free fatty acids as biomarkers for the identification of lung cancer.
Detailed description
We will compare the concentration of free fatty acids and their metabolites between patients with lung cancer and control pulmonary patients without known cancer. The diagnostic accuracy will be assessed for potential predictors.
Interventions
OTHERserum sample
Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank
Sponsors
The Cleveland Clinic
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age from 40 to 80 * Lung adenocarcinoma with pathological diagnosis * Lung squamous cell carcinoma with pathological diagnosis * Control patients should have at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.
Exclusion criteria
\- Lung cancer patient without serum sample before the initiation of treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Compare Concentration of Fatty Acids and Their Metabolites | At the time of diagnosis, prior to the initiation of lung cancer treatment | Biochemical analysis of serum sample was conducted by an investigator who was strictly blinded to cancer status and patient characteristics. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Lung Adenocarcinoma Patients Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung adenocarcinoma was based on pathologic analysis.
serum sample: Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank | 37 |
| Control Matched to Adenocarcinoma Control subjects without known cancer and aged from 40 to 75 years should meet at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.
serum sample: Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank | 111 |
| Lung Squamous Cell Carcinoma Patients Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung squamous cell carcinoma was based on pathologic analysis.
serum sample: Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank | 18 |
| Control Matched to Squamous Cell Control subjects without known cancer and aged from 40 to 75 years should meet at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.
serum sample: Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank | 54 |
| Total | 220 |
Baseline characteristics
| Characteristic | Control Matched to Squamous Cell | Total | Lung Adenocarcinoma Patients | Control Matched to Adenocarcinoma | Lung Squamous Cell Carcinoma Patients |
|---|---|---|---|---|---|
| Age, Continuous | 68 years STANDARD_DEVIATION 6 | 66 years STANDARD_DEVIATION 7 | 66 years STANDARD_DEVIATION 11 | 65 years STANDARD_DEVIATION 6 | 70 years STANDARD_DEVIATION 9 |
| Amount of Cigarette Smoking as Pack-year | 39 pack-year | 40 pack-year | 40 pack-year | 40 pack-year | 38 pack-year |
| COPD | 11 Participants | 58 Participants | 10 Participants | 32 Participants | 5 Participants |
| Family history of lung cancer | 16 Participants | 48 Participants | 6 Participants | 21 Participants | 5 Participants |
| Sex: Female, Male Female | 24 Participants | 84 Participants | 13 Participants | 40 Participants | 7 Participants |
| Sex: Female, Male Male | 30 Participants | 136 Participants | 24 Participants | 71 Participants | 11 Participants |
| Smoking status Current | 12 participants | 56 participants | 9 participants | 32 participants | 3 participants |
| Smoking status Former | 39 participants | 157 participants | 27 participants | 76 participants | 15 participants |
| Smoking status Never | 3 participants | 7 participants | 1 participants | 3 participants | 0 participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 37 | 0 / 111 | 0 / 18 | 0 / 54 |
| other Total, other adverse events | 0 / 37 | 0 / 111 | 0 / 18 | 0 / 54 |
| serious Total, serious adverse events | 0 / 37 | 0 / 111 | 0 / 18 | 0 / 54 |
Outcome results
Primary
Compare Concentration of Fatty Acids and Their Metabolites
Biochemical analysis of serum sample was conducted by an investigator who was strictly blinded to cancer status and patient characteristics.
Time frame: At the time of diagnosis, prior to the initiation of lung cancer treatment
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Lung Adenocarcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | Arachidonic Acid | 5.70 mg/mL |
| Lung Adenocarcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | 12-hydroxyeicosatetraenoic acid | 0.94 mg/mL |
| Lung Adenocarcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | C16-lysophospholipid platelet activating factor | 0.0 mg/mL |
| Lung Adenocarcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | Hydroperoxyoctadecadienoyl phosphatidylcholine | 22.3 mg/mL |
| Lung Adenocarcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | 5-hydroxyeicosatetraenoic acid | 0.05 mg/mL |
| Lung Adenocarcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | 11-hydroxyeicosatetraenoic acid | 0.07 mg/mL |
| Lung Adenocarcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | Hydroxyoctadecadienoylphosphatidylcholine | 2.5 mg/mL |
| Lung Adenocarcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | Linoleic Acid | 0.59 mg/mL |
| Lung Adenocarcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | 9-hydroxyoctadecadienoic acid | 0.56 mg/mL |
| Lung Adenocarcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | Azelaoyl platelet activating factor | 0.4 mg/mL |
| Lung Adenocarcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | Azelaoyl phosphatidylcholine | 0.2 mg/mL |
| Lung Adenocarcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | 15-hydroxyeicosatetraenoic acid | 0.02 mg/mL |
| Lung Adenocarcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | C18-lysophospholipid platelet activating factor | 12.7 mg/mL |
| Lung Adenocarcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | 13-hydroxyoctadecadienoic acid | 0.43 mg/mL |
| Lung Adenocarcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | C16-lyso-phosphatidylcholine | 8.3 mg/mL |
| Control Matched to Adenocarcinoma | Compare Concentration of Fatty Acids and Their Metabolites | C16-lyso-phosphatidylcholine | 9.8 mg/mL |
| Control Matched to Adenocarcinoma | Compare Concentration of Fatty Acids and Their Metabolites | 12-hydroxyeicosatetraenoic acid | 0.23 mg/mL |
| Control Matched to Adenocarcinoma | Compare Concentration of Fatty Acids and Their Metabolites | Azelaoyl platelet activating factor | 0.5 mg/mL |
| Control Matched to Adenocarcinoma | Compare Concentration of Fatty Acids and Their Metabolites | C16-lysophospholipid platelet activating factor | 0.0 mg/mL |
| Control Matched to Adenocarcinoma | Compare Concentration of Fatty Acids and Their Metabolites | Linoleic Acid | 0.34 mg/mL |
| Control Matched to Adenocarcinoma | Compare Concentration of Fatty Acids and Their Metabolites | 11-hydroxyeicosatetraenoic acid | 0.03 mg/mL |
| Control Matched to Adenocarcinoma | Compare Concentration of Fatty Acids and Their Metabolites | 15-hydroxyeicosatetraenoic acid | 0.01 mg/mL |
| Control Matched to Adenocarcinoma | Compare Concentration of Fatty Acids and Their Metabolites | 5-hydroxyeicosatetraenoic acid | 0.03 mg/mL |
| Control Matched to Adenocarcinoma | Compare Concentration of Fatty Acids and Their Metabolites | Hydroperoxyoctadecadienoyl phosphatidylcholine | 17.9 mg/mL |
| Control Matched to Adenocarcinoma | Compare Concentration of Fatty Acids and Their Metabolites | C18-lysophospholipid platelet activating factor | 16.5 mg/mL |
| Control Matched to Adenocarcinoma | Compare Concentration of Fatty Acids and Their Metabolites | 13-hydroxyoctadecadienoic acid | 0.48 mg/mL |
| Control Matched to Adenocarcinoma | Compare Concentration of Fatty Acids and Their Metabolites | 9-hydroxyoctadecadienoic acid | 0.58 mg/mL |
| Control Matched to Adenocarcinoma | Compare Concentration of Fatty Acids and Their Metabolites | Azelaoyl phosphatidylcholine | 0.2 mg/mL |
| Control Matched to Adenocarcinoma | Compare Concentration of Fatty Acids and Their Metabolites | Hydroxyoctadecadienoylphosphatidylcholine | 7.1 mg/mL |
| Control Matched to Adenocarcinoma | Compare Concentration of Fatty Acids and Their Metabolites | Arachidonic Acid | 2.95 mg/mL |
| Lung Squamous Cell Carcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | C16-lyso-phosphatidylcholine | 12 mg/mL |
| Lung Squamous Cell Carcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | Arachidonic Acid | 4.24 mg/mL |
| Lung Squamous Cell Carcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | Linoleic Acid | 0.44 mg/mL |
| Lung Squamous Cell Carcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | Hydroperoxyoctadecadienoyl phosphatidylcholine | 18 mg/mL |
| Lung Squamous Cell Carcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | Hydroxyoctadecadienoylphosphatidylcholine | 4 mg/mL |
| Lung Squamous Cell Carcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | Azelaoyl platelet activating factor | 0.5 mg/mL |
| Lung Squamous Cell Carcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | Azelaoyl phosphatidylcholine | 0.2 mg/mL |
| Lung Squamous Cell Carcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | C18-lysophospholipid platelet activating factor | 13 mg/mL |
| Lung Squamous Cell Carcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | C16-lysophospholipid platelet activating factor | 0.0 mg/mL |
| Lung Squamous Cell Carcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | 5-hydroxyeicosatetraenoic acid | 0.04 mg/mL |
| Lung Squamous Cell Carcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | 11-hydroxyeicosatetraenoic acid | 0.04 mg/mL |
| Lung Squamous Cell Carcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | 12-hydroxyeicosatetraenoic acid | 0.42 mg/mL |
| Lung Squamous Cell Carcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | 15-hydroxyeicosatetraenoic acid | 0.01 mg/mL |
| Lung Squamous Cell Carcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | 9-hydroxyoctadecadienoic acid | 0.52 mg/mL |
| Lung Squamous Cell Carcinoma Patients | Compare Concentration of Fatty Acids and Their Metabolites | 13-hydroxyoctadecadienoic acid | 0.49 mg/mL |
| Control Matched to Squamous Cell | Compare Concentration of Fatty Acids and Their Metabolites | C18-lysophospholipid platelet activating factor | 17 mg/mL |
| Control Matched to Squamous Cell | Compare Concentration of Fatty Acids and Their Metabolites | Linoleic Acid | 0.32 mg/mL |
| Control Matched to Squamous Cell | Compare Concentration of Fatty Acids and Their Metabolites | 12-hydroxyeicosatetraenoic acid | 0.22 mg/mL |
| Control Matched to Squamous Cell | Compare Concentration of Fatty Acids and Their Metabolites | Azelaoyl phosphatidylcholine | 0.2 mg/mL |
| Control Matched to Squamous Cell | Compare Concentration of Fatty Acids and Their Metabolites | Azelaoyl platelet activating factor | 0.5 mg/mL |
| Control Matched to Squamous Cell | Compare Concentration of Fatty Acids and Their Metabolites | Arachidonic Acid | 3.18 mg/mL |
| Control Matched to Squamous Cell | Compare Concentration of Fatty Acids and Their Metabolites | 15-hydroxyeicosatetraenoic acid | 0.01 mg/mL |
| Control Matched to Squamous Cell | Compare Concentration of Fatty Acids and Their Metabolites | Hydroxyoctadecadienoylphosphatidylcholine | 9 mg/mL |
| Control Matched to Squamous Cell | Compare Concentration of Fatty Acids and Their Metabolites | Hydroperoxyoctadecadienoyl phosphatidylcholine | 18 mg/mL |
| Control Matched to Squamous Cell | Compare Concentration of Fatty Acids and Their Metabolites | 13-hydroxyoctadecadienoic acid | 0.44 mg/mL |
| Control Matched to Squamous Cell | Compare Concentration of Fatty Acids and Their Metabolites | 5-hydroxyeicosatetraenoic acid | 0.03 mg/mL |
| Control Matched to Squamous Cell | Compare Concentration of Fatty Acids and Their Metabolites | C16-lysophospholipid platelet activating factor | 0.1 mg/mL |
| Control Matched to Squamous Cell | Compare Concentration of Fatty Acids and Their Metabolites | 9-hydroxyoctadecadienoic acid | 0.51 mg/mL |
| Control Matched to Squamous Cell | Compare Concentration of Fatty Acids and Their Metabolites | 11-hydroxyeicosatetraenoic acid | 0.03 mg/mL |
| Control Matched to Squamous Cell | Compare Concentration of Fatty Acids and Their Metabolites | C16-lyso-phosphatidylcholine | 13 mg/mL |